Treace Medical Concepts, Inc.

Equities

TMCI

US89455T1097

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 04:00:00 2024-06-18 pm EDT 5-day change 1st Jan Change
6.03 USD -0.82% Intraday chart for Treace Medical Concepts, Inc. +3.08% -52.71%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Treace Medical Concepts Insider Bought Shares Worth $253,475, According to a Recent SEC Filing MT
North American Morning Briefing : The "Everything -2- DJ
UBS Downgrades Treace Medical Concepts to Neutral From Buy, Cuts Price Target to $6.50 From $16 MT
Transcript : Treace Medical Concepts, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 02:20 PM
Top Midday Decliners MT
UBS Adjusts Price Target on Treace Medical Concepts to $16 From $17, Maintains Buy Rating MT
Truist Downgrades Treace Medical Concepts to Hold From Buy, Cuts PT to $7 From $17; Notes Slowing Growth Outlook Amid Rising Competitive Pressures MT
Top Premarket Decliners MT
Truist Securities Downgrades Treace Medical Concepts to Hold From Buy, Lowers Price Target to $7 From $17 MT
BTIG Downgrades Treace Medical Concepts to Neutral From Buy MT
JPMorgan Downgrades Treace Medical Concepts to Neutral From Overweight, Cuts Price Target to $8 From $15 MT
Stifel Downgrades Treace Medical Concepts to Hold From Buy, Cuts Price Target to $6 From $15 MT
Treace Medical Concepts Falls 57% Premarket After Revising 2024 Sales Outlook to $201-$211 Million From $220-$225 Million MT
Earnings Flash (TMCI) TREACE MEDICAL CONCEPTS Reports Q1 Revenue $51.1M, vs. Street Est of $49.1M MT
Transcript : Treace Medical Concepts, Inc., Q1 2024 Earnings Call, May 07, 2024
Treace Medical Concepts, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Treace Medical Concepts, Inc. Revises Earnings Guidance for the Full-Year 2024 CI
Treace Medical Concepts Treats 100,000 Patients With Lapiplasty Bunion Correction MT
Transcript : Treace Medical Concepts, Inc., Q4 2023 Earnings Call, Feb 27, 2024
Treace Medical Concepts, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Earnings Flash (TMCI) TREACE MEDICAL CONCEPTS Reports Q4 Revenue $62.2M, vs. Street Est of $60.2M MT
Treace Medical Concepts, Inc. Provides Revenue Guidance for the Year 2024 CI
Treace Medical Concepts, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Treace Medical Concepts Says Post-Market Study of Lapiplasty Shows Patients Report 'Positive' Outcomes MT
Treace Medical Concepts, Inc. Announces Three-Year Interim Data from Its Align3d?? Post-Market Study Supporting the Use of the Lapiplasty Procedure for Treating Bunions CI
Chart Treace Medical Concepts, Inc.
More charts
Treace Medical Concepts, Inc. is a medical technology company. The Company is focused on advancing the standard of care for the surgical management of bunion and related midfoot deformities. It has patented the Lapiplasty 3D Bunion Correction System a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. It also has Adductoplasty Midfoot Correction System, designed for reproducible surgical correction of the midfoot as well as its Hammertoe PEEK Fixation System designed to address hammertoe, claw toe and mallet toe deformities. The Lapiplasty, Adductoplasty and Hammertoe PEEK Fixation Systems are comprised of single-use implant kits and reusable instrument trays. The Company sells these products to physicians, surgeons, hospitals and ambulatory surgery centers in the United States.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
7
Last Close Price
6.03 USD
Average target price
6.833 USD
Spread / Average Target
+13.32%
Consensus